Major Depressive Disorder Clinical Trial
Official title:
Efficacy and Safety of Aripiprazole 2.5mg Combine Sertraline 50mg in Major Depression
Verified date | April 2009 |
Source | Chimei Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
FDA has accepted atypical antipsychotics of olanzapine and aripiprazole as the adjuvant medications for refractory major depression. But there is still no trial about atypical antipsychotics combined with antidepressant of SSRI used in fresh major depressive patients. This project aims to compare the efficacy and tolerability of sertraline with or without low-dosed aripiprazole added in fresh major depression.
Status | Completed |
Enrollment | 41 |
Est. completion date | March 2009 |
Est. primary completion date | March 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male or female subjects 18 to 65 years inclusive. - Fulfilled DSM-? criteria for major depressive disorder. - Onset ?2 weeks. - Baseline score ?14 on the HAM-D17. - Written informed consent prior to entry into the study. Exclusion Criteria: - HAM-D17 item 3 score?3. - Life-time history of bipolar disorders, schizophrenia or schizoaffective disorder. - Current history of panic disorder, obsessive-compulsive disorder, alcohol or substance abuse. - Mood disorder due to general medical condition. - Treatment with antidepressants at entry into the study before 2 weeks. - Need for psychoactive medications other than the study drugs, except for one benzodiazepine or hypnotic given at a stable dose. - Known intolerance or inefficacy to either drug. - Previous lack of response to two or more antidepressants at adequate dosage. - Subjects who have acute or unstable medical illness or organic failure. - Pregnancy and breast-feeding. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Psychiatry Department, Chimei Medical Center | Tainan |
Lead Sponsor | Collaborator |
---|---|
Chimei Medical Center |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | score change of Hamilton Rating Scale For Depression (HAM-D17 ) | day 1 / 1 week / 2 weeks/ 4 weeks/ 6 weeks/ 10weeks | ||
Secondary | score change of Brief Psychiatric Rating Scale (BPRS-50) | day 1/ 1 week / 2 weeks/ 4 weeks/ 6 weeks/ 10 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |